ONCO
Price
$3.76Alerts
Change
+$0.29 (+8.36%)
Updated
Nov 11 closing price
Capitalization
30.44M
Earnings call today
Intraday BUY SELL Signals
PCSA
Price
$1.87Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
5.31M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

ONCO vs PCSA

ONCO vs PCSA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ONCO vs. PCSA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ONCO is a Hold and PCSA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ONCO with price predictions
Nov 11, 2026

ONCO's RSI Indicator recovers from oversold territory

The RSI Indicator for ONCO moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +21.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCO advanced for three days, in 142 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONCO as a result. In 76 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for ONCO turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In 33 of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

ONCO moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ONCO crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

ONCO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ONCO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.260) is normal, around the industry mean (3.498). P/E Ratio (0.009) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.598) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PCSA with price predictions
Nov 11, 2026

PCSA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for PCSA turned positive on October 12, 2026. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PCSA's RSI Oscillator exited the oversold zone, 40 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PCSA as a result. In 66 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

PCSA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PCSA crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in 183 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 49 of 57 cases where PCSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 33 cases where PCSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.725) is normal, around the industry mean (3.498). P/E Ratio (2.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PCSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
PCSA: Fundamental Ratings
PCSA
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
63
SEASONALITY SCORE
1..100
1

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ONCOPCSA
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ONCO: $3.76 vs. PCSA: $1.87)
Brand notoriety: ONCO and PCSA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ONCO: 12% vs. PCSA: 21%
Market capitalization -- ONCO: $30.44M vs. PCSA: $5.31M
ONCO [@Biotechnology] is valued at $30.44M. PCSA’s [@Biotechnology] market capitalization is $5.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ONCO’s FA Score shows that 1 FA rating(s) are green while PCSA’s FA Score has 1 green FA rating(s).

  • ONCO’s FA Score: 1 green, 4 red.
  • PCSA’s FA Score: 1 green, 4 red.
According to our system of comparison, PCSA is a better buy in the long-term than ONCO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ONCO’s TA Score shows that 3 TA indicator(s) are bullish while PCSA’s TA Score has 7 bullish TA indicator(s).

  • ONCO’s TA Score: 3 bullish, 7 bearish.
  • PCSA’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, PCSA is a better buy in the short-term than ONCO.

Price Growth

ONCO (@Biotechnology) experienced а -42.88% price change this week, while PCSA (@Biotechnology) price change was -3.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

ONCO is expected to report earnings on Nov 12, 2026.

PCSA is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ONCO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ONCO has been loosely correlated with PCSA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ONCO jumps, then PCSA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONCO
1D Price
Change %
ONCO100%
+8.36%
PCSA - ONCO
35%
Loosely correlated
N/A
ZURA - ONCO
33%
Loosely correlated
+1.78%
ABEO - ONCO
29%
Poorly correlated
-6.31%
NIKI - ONCO
28%
Poorly correlated
-2.48%
NBTX - ONCO
25%
Poorly correlated
+0.24%
More

PCSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCSA has been loosely correlated with RADX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PCSA jumps, then RADX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCSA
1D Price
Change %
PCSA100%
N/A
RADX - PCSA
48%
Loosely correlated
-2.35%
INO - PCSA
38%
Loosely correlated
+1.72%
ONCO - PCSA
35%
Loosely correlated
+8.36%
IBO - PCSA
32%
Poorly correlated
-6.93%
EDIT - PCSA
28%
Poorly correlated
-4.99%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INOD38.173.12
+8.90%
Innodata
HCA506.041.62
+0.32%
HCA Healthcare
EPRT27.97-0.10
-0.36%
Essential Properties Realty Trust
LVLU11.43-0.12
-1.04%
Lulu's Fashion Lounge Holdings Inc
QTTB9.20-0.13
-1.39%
Q32 Bio